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Abstract
 
Carbon monoxide (CO) and nitric oxide (NO) each have mechanistically unique roles in various
inflammatory disorders. Although it is known that CO can induce production of NO and that
NO can induce expression of the cytoprotective enzyme heme oxygenase 1 (HO-1), there is
no information whether the protective effect of CO ever requires NO production or whether
either gas must induce expression of HO-1 to exert its functional effects. Using in vitro and in
vivo models of tumor necrosis factor 
 
 
 
–induced hepatocyte cell death in mice, we find that
activation of nuclear factor 
 
 
 
B and increased expression of inducible NO are required for the
protective effects of CO, whereas the protective effects of NO require up-regulation of HO-1
expression. When protection from cell death is initiated by CO, NO production and HO-1
activity are each required for the protective effect showing for the first time an essential synergy
between these two molecules in tandem providing potent cytoprotection.
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Introduction
 
Inflammation and stress result in the induction of “protective
genes” such as the inducible forms of heme oxygenase 1
(HO-1) and nitric oxide (NO) synthase II (inducible NO
synthase [iNOS]) that generate the gaseous molecules carbon
monoxide (CO) and NO, respectively. Both HO-1 and
iNOS are cytoprotective enzymes and when expressed
produce therapeutic benefits in a number of conditions/
diseases. We and others have previously demonstrated that
iNOS/NO is protective in models of fulminant hepatic
failure (1, 2). HO-1 overexpression has been demonstrated
to be cytoprotective in multiple models including endotox-
emia (3), shock (4), ischemia/reperfusion (5, 6), and xenograft
rejection (7). Recent findings suggest that one mechanism
by which HO-1 protects is via generation of CO after the
degradation of heme by HO-1 (8, 9).
These two gases are linked in that NO can up-regulate
HO-1 expression leading to the formation of endogenous
CO (10), and CO can bind to the heme group in the iNOS
protein and influence the production of NO (11, 12).
However, there is no information about any requisite func-
tional interactions between the effects of CO and NO and
the respective enzymes leading to their production. We
hypothesized that in some cases CO requires up-regulation
of iNOS and production of NO in mediating protective
effects and that subsequent NO generation requires HO-1
induction to mediate its therapeutic effects. We have studied
the role of iNOS and NO in a model of fulminant hepatic
failure in which CO confers protective effects both in vitro
and in vivo. Our findings demonstrate a system of interde-
pendence: exogenous CO protects through a nuclear factor
(NF)-
 
 
 
B–mediated, iNOS-dependent mechanism with NO
subsequently protecting, at least in part, through an HO-1–
dependent mechanism. Additionally, the protective effects
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 ActD, actinomycin-D; ALT, alanine ami-
notransferase; APAP, acetaminophen; A.U., arbitrary units; CM, cytokine
mixture; CO, carbon monoxide; CoPP, cobalt protoporphyrin; D-gal,
D-galactosamine; EMSA, electrophoretic mobility shift assay; H&E, hema-
toxylin and eosin; HO-1, heme oxygenase 1; iNOS, inducible nitric oxide
synthase; L-NIL, L-N6-(1-iminoethyl)-lysine-dihydrochloride; L-NIO,
L-N5-(1-iminoethyl)-ornithine-2HCl; NF, nuclear factor; NO, nitric
oxide; SNAP, s-nitroso-
 
N
 
-acetyl-penicillamine; SnPP, tin protoporphyrin;
V-PYRRO, O
 
2
 
-vinyl 1-(pyrrolidin-1-yl) diazen-1-ium-1,2-diolate. 
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initiated by CO are ultimately mediated, in part, via up-
regulation of HO-1. Other roles NO plays in providing
protection initiated by CO in this model are not clear. We
show that each of these steps, iNOS induction/NO pro-
duction and activation of HO-1 expression, is obligatory to
obtain the therapeutic benefit initiated by CO.
 
Materials and Methods
 
Acute Hepatic Injury Models.
 
All experiments were approved
by the institutional animal care and use committee of the Univer-
sity of Pittsburgh. Male C57BL/6J (Charles River Laboratories),
8–12-wk-old 
 
inos
 
 
 
/
 
  
 
mice and wild-type littermates (bred/main-
tained at the University of Pittsburgh) were used for in vivo ex-
periments. Groups of mice were administered 0.3 
 
 
 
g TNF-
 
 
 
/8
mg D-galactosamine (D-gal)/mouse i.p. Depending on the exper-
imental condition, some mice received 250 ppm CO, 10 mg/kg
of the selective NO donor O
 
2
 
-vinyl 1-(pyrrolidin-1-yl) diazen-1-
ium-1,2-diolate (V-PYRRO; Qbiogene) s.c., or 5 mg/kg cobalt
protoporphyrin (CoPP; Frontier Scientific) i.p. Additionally, 5
mg/kg of the selective inhibitor of iNOS L-N6-(1-iminoethyl)-
lysine-dihydrochloride (L-NIL; Qbiogene) or 50 
 
 
 
mol/kg of the
HO-1 inhibitor tin protoporphyrin (SnPP; Frontier Scientific) was
administered i.p. when specified. Where indicated, 500 mg/kg
acetaminophen (APAP; Sigma-Aldrich) was administered i.p.
 
Hepatocyte Cell Culture.
 
Mouse primary hepatocytes were
harvested from C57BL/6J, 
 
mkk3
 
 
 
/
 
 
 
, 
 
inos
 
 
 
/
 
  
 
(in house breeding
colony), or 
 
hmox-1
 
 
 
/
 
  
 
(provided by E. Nabel, National Heart,
Lung, and Blood Institute, Bethesda, MD, and S. Yet, Harvard
Medical School, Boston, MA) mice as previously described (13).
Hepatocytes were used on days 1–3 after the harvest.
 
Induction of Hepatocyte Death/Apoptosis.
 
Cells were treated
with 10 ng/ml TNF-
 
  
 
and 200 ng/ml actinomycin-D (ActD;
Sigma-Aldrich) to induce cell death. TNF-
 
 
 
/ActD treatment has
previously been demonstrated to induce cell death, specifically
apoptosis, in primary hepatocytes (13). Hepatocytes were treated
with CO, 250–750 
 
 
 
M of the NO donor s-nitroso-
 
N
 
-acetyl-
penicillamine (SNAP), and/or additional pharmacologic agents
when specified. 12 h after TNF-
 
 
 
/ActD treatment, cells were
washed and stained with crystal violet to determine viability as
previously described (13). Where specified, 1–2 mM of the selec-
tive in vitro inhibitor of iNOS, L-N5-(1-iminoethyl)-ornithine-
2HCl (L-NIO; Calbiochem), was used.
 
Gene Transfer/Plasmids.
 
In some experiments, gene transfer of
an I
 
 
 
B
 
  
 
super repressor (provided by D. Brenner, University of
North Carolina, Chapel Hill, NC; reference 14) or 
 
 
 
-galactosi-
dase using adenoviral vectors (10 PFU/cell) was performed 12 h
before TNF-
 
 
 
/ActD treatment. Evaluation of NF-
 
 
 
B activation
was performed using a luciferase reporter assay as previously de-
scribed. (15) In brief, hepatocytes were cotransfected with NF-
 
 
 
B reporter constructs (100 ng/well; pGL3-
 
   
 
luciferase; pro-
vided by D. Golenbock, University of Massachusetts, Worcester,
MA) and pIEP-Lac-z (0.5 
 
 
 
g/well) using Lipofectin (Invitrogen)
according to the manufacturer’s instructions. Evaluation of iNOS
expression was performed using a luciferase reporter assay as pre-
viously described (16). In brief, hepatocytes were cotransfected
with iNOS promoter reporter constructs (1 
 
 
 
g/well; pXP2; pro-
vided by C. Lowenstein, Johns Hopkins University, Baltimore,
MD) and pIEP-LacZ (0.5 
 
 
 
g/well) as described above.
 
Luciferase Reporter Assays.
 
Hepatocytes were transfected with
plasmids as described above. Hepatocytes were treated with vari-
ous stimuli 24 h after transfection (see Results). Luciferase activity
(reported as arbitrary units [A.U.]) was assayed 6 h after initiation
of treatment using a luciferase assay kit (Promega) according to
the manufacturer’s instructions and measured on a Berthold Lu-
minometer. Results were corrected for transfection efficiency and
protein concentration.
 
Electrophoretic Mobility Shift Assay (EMSA).
 
Nuclei were ex-
tracted from hepatocytes after specified treatment. A double
stranded DNA NF-
 
 
 
B consensus sequence (GGGGACTTT-
CCC; Santa Cruz Biotechnology, Inc.) was labeled with [
 
 
 
-
 
32
 
P]-
ATP and then incubated with 5 mg total nuclear protein. Some
incubations were performed in the presence of antibodies against
p65/RelA or p50 (Santa Cruz Biotechnology, Inc.) to evaluate
for supershift. EMSAs were performed as previously described
(17).
 
Immunoblot Analysis.
 
Western blot analysis was performed on
primary hepatocytes in culture or from liver homogenates with
antibodies to iNOS (1:1,000; Transduction Laboratories), HO-1
(1:2,000; Calbiochem), or 
 
 
 
-actin (1:5,000; Sigma-Aldrich). 30
 
 
 
g protein in cell culture experiments or 100 
 
 
 
g protein from
liver homogenates was loaded per well for SDS-PAGE.
 
Histology/Immunohistochemistry.
 
For histology and immuno-
histochemistry, livers were fixed in 2% paraformaldehyde and
then snap frozen in liquid nitrogen. Livers were then sectioned (7
microns thick) and stained with hematoxylin and eosin (H&E).
Liver sections were also stained for TUNEL and activated caspase
3 using kits according to the manufacturer’s instructions
(Promega). Sections for iNOS immunocytochemistry were
blocked with 5% goat serum containing 0.2% bovine serum albu-
min. Thereafter, sections were incubated for 1 h at room temper-
ature with anti-iNOS antibody (1:300; Transduction Laborato-
ries), and then washed and probed with a secondary antibody
conjugated to Alexa 488 (Molecular Probes). Nuclei were stained
with Hoechst dye. Images were acquired using an Olympus Pro-
vus microscope. Hepatocytes in culture were plated on gelati-
nized coverslips, stimulated as indicated, and then fixed in 2%
paraformaldehyde containing 0.1% Triton X-100. Blocking and
staining was similar to liver sections except that anti-p65/RelA
antibody (1:350; Santa Cruz Biotechnology, Inc.) was used.
 
Results
 
HO-1 Protects against Liver Injury.
 
Pharmacological in-
duction or gene transfer of HO-1 is hepatoprotective in
models of ischemia/reperfusion (5), endotoxemia (3), hy-
Figure 1. HO-1 protects against acute hepatitis. Male C57BL/6J mice
were administered 5 mg/kg CoPP i.p. 24 h before 0.3  g TNF- /8 mg
D-gal/mouse i.p. Serum ALT was determined 8 h later. Results are the
mean   SD of six to eight mice/group. *, P   0.005. 
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Figure 2. NF- B activation is crucial in the ability of CO to provide
cytoprotection against TNF- /ActD-induced cell death. (a) Cells were
preincubated with 250 ppm CO for 1 h (standard pretreatment time for
all experiments) before the addition of 10 ng TNF- /200 ng/ml ActD.
Cells were maintained in CO for the duration of the experiment. 12 h
thereafter, cell viability was determined as previously described (refer-
ence 13). Adenoviral experiments involved incubating hepatocytes
overnight with 10 PFU/cell of the adenovirus before the addition of
TNF- /ActD. Hepatocytes were then assayed for viability by crystal
violet. To evaluate the role of cGMP and confirm the role of NF- B, hepatocytes were treated separately with 2–10 M of the soluble guanylate
cyclase inhibitor 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one or 10  M of the NF- B inhibitor BAY 11-7082. Treatment with the inhibitors was
for 1 h before the 1-h pretreatment with CO. TNF- /ActD was then added and the cells were tested for viability 12 h later. Note that NF- B activation
was critical to the protection elicited by CO whereas cGMP was not involved. Exposure to CO led to suppression of cell death that was significantly
lower (*, P   0.01) than without CO. Results shown are the mean   SE of triplicate wells from four independent experiments. (b) Human primary
hepatocytes obtained from a donor liver resection (provided by S. Strom, University of Pittsburgh, Pittsburgh, PA) were treated with CO and TNF-
 /ActD as described above. A similar protective effect of CO was observed. Results are mean   SD of triplicate wells from three independent experi-
ments. *, P   0.05. (c) Evaluation of NF- B activation was performed using a luciferase reporter assay as previously described (reference 15). In
brief, hepatocytes were cotransfected with NF- B reporter constructs and pIEP-Lac-z 24 h before the addition of 10  M BAY 11-7082 or vehicle.
Cells were incubated for 1 h before 250 ppm CO. Luciferase activity (reported as A.U.) was assayed 6 h after exposure to CO or a CM composed of
500 U/ml TNF- , 100 U/ml IL-1 , and 100 U/ml IFN , which was used as a positive control for NF- B activation. Results were corrected for
transfection efficiency and protein concentration. Results shown are the mean   SE of triplicate wells from three independent experiments. *, P   0.001
versus Air. (d) NF- B DNA binding evaluated by EMSA in hepatocytes treated with 250 ppm CO. Note the time-dependent increase in NF- B
binding (total) with expression peaking at 1 h (lanes 1, 4, and 7). Extracts were then supershifted to identify the different NF- B dimers using anti-
bodies against p50 (lanes 2, 5, and 8) and p65 (lanes 3, 6, and 9). Results are representative of two independent experiments. (e) Immunostaining for
nuclear p65 localization in primary hepatocytes after 1 h exposure to 250 ppm CO. Images depict nuclear translocation of NF- B (arrows pointing
to green nuclei that depict the translocation of NF- B) in both CM (used as a positive control) and CO-treated cells versus no localization in air-treated
cells (arrows pointing to blue nuclei). Images are representative of six different fields. Bar, 10  m. 
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peroxic lung injury (18), and hemorrhagic shock (19).
Consistent with these findings, Sass et al. (20) showed that
mice were more prone to TNF-
 
 
 
–induced hepatocyte cell
death when HO-1 was inhibited. To study whether HO-1
is protective in a model of acute hepatic failure, we in-
duced HO-1 expression in C57BL/6J mice by administer-
ing CoPP and then administering TNF-
 
 
 
/D-gal. Induc-
tion of HO-1 was able to prevent the injury as measured
by serum alanine aminotransferase (ALT) levels (Fig. 1).
 
CO Protects Hepatocytes.
 
Based on the protection con-
ferred by HO-1 in vivo, we asked if exogenous CO would
protect against hepatocyte cell death in vitro. Exposure of
primary mouse, rat, and human hepatocytes to 250 ppm
CO inhibited TNF-
 
 
 
–induced apoptosis (Fig. 2, a and b),
consistent with previous data showing inhibition of cell
death in endothelial cells (21), 
 
 
 
 cells (22), and fibroblasts
(23). As the effects of CO in other models were mediated
by guanylyl cyclase and/or p38 MAPK (21, 24), the role of
these signaling molecules was investigated in this model.
Inhibition of hepatocyte apoptosis was independent of
cGMP generation, as the selective guanylyl cyclase inhibi-
tor 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (Calbio-
chem) did not reverse the protection provided by CO (Fig.
2 a). Additionally, CO treatment inhibited cell death both
in the presence of 3–30 
 
 
 
M SB203580 (Calbiochem), a se-
lective inhibitor of p38 MAPK activation, and in hepato-
cytes from 
 
mkk3
 
 
 
/
 
  
 
mice, the dominant upstream kinase
for p38 (not depicted). Thus, the effects of CO were inde-
pendent of the cGMP/p38 MAPK pathway. In all of these
experiments, hepatocytes were pretreated with CO for 1 h
before the addition of TNF-
 
 
 
/ActD to the medium. If the
CO treatment was started after the addition of TNF-
 
 
 
,
there was less protection (not depicted). We hypothesize
that the CO pretreatment primes the molecular machinery
in the cells such that upon stimulation with TNF-
 
 
 
, the
 
antiapoptotic/survival pathways will predominate over the
proapoptotic pathways.
 
CO-induced Protection Requires NF-
 
 
 
B.
 
The role of NF-
 
 
 
B in the liver as part of a prosurvival signaling pathway has
been studied (25). We demonstrate here in mouse hepato-
cytes that CO induced an increase in NF-
 
 
 
B nuclear trans-
location and DNA binding as measured by EMSA, immu-
nostaining for RelA/p65 nuclear translocation, and NF-
 
 
 
B
luciferase reporter assay activity that peaked 1 h after placing
cells in the CO atmosphere (Fig. 2, c–e). A cytokine mix-
ture (CM) was included in the treatment groups as a positive
signal as well as a standard for maximum reporter activity by
which to evaluate the effects of CO. Transfection efficiency
in primary hepatocytes is difficult, but even given this prob-
lem, our reporter activity was very significant (
 
*
 
, P 
 
  
 
0.001
vs. control). These data combined with our positive immu-
nostaining and EMSA results support the notion that CO
induces a moderate increase in NF-
 
 B that in itself may in
part result in selective gene expression. To evaluate whether
NF- B activity is needed for protection mediated by CO,
we used adenoviral gene transfer of I B  to prevent NF- B
translocation (14) or 1–10 mM BAY 11-7082 (Calbiochem)
to inhibit NF- B activation. The protective effects of CO
were abrogated by inhibition of NF- B activation (Fig. 2 a).
NF- B is known to be involved in the regulation of many
antiapoptotic genes (21, 26, 27), some of which may play a
role in the cytoprotection conferred by CO.
CO Requires NF- B–dependent iNOS Expression for Pro-
tection of Hepatocytes. Overexpression of iNOS and NO
donors are protective in models of hepatocyte apoptosis
similar to the one studied here (13, 28, 29). Because iNOS
gene expression is regulated by NF- B (17), we asked if
protection mediated by CO requires expression of iNOS
and generation of NO. Exposure of hepatocytes to CO
produced a highly significant increase in activity in an iNOS
Figure 3. The role of iNOS in CO-induced
cytoprotection from TNF- /ActD-induced cell
death. (a) Evaluation of iNOS expression was
performed using a luciferase reporter assay as
previously described (16). In brief, hepatocytes
were cotransfected with an iNOS promoter
reporter construct and pIEP-LacZ 24 h before exposure to 10  M BAY 11-7082
or vehicle. Cells were incubated with BAY 1 h before exposure to 250 ppm CO.
Luciferase activity (reported as A.U.) was assayed as described above. CM (see
above) was used as a positive control to induce iNOS expression and results were
corrected for transfection efficiency and protein concentration. Results shown are
the mean   SE of triplicate wells from four independent experiments. *, P   0.001
versus air- and air/BAY-treated cells. (b) Expression of iNOS protein was evalu-
ated by immunoblotting. In brief, cell extracts from hepatocytes were treated with
TNF- /ActD for 6–8 h in the presence and absence of 250 ppm CO. Control cells
received air or CO alone. Note that TNF-  induces iNOS expression minimally,
whereas those cells treated with TNF-  in the presence of CO show a significantly
greater induction in iNOS protein. The immunoblot is representative of three
independent experiments. (c) Mouse hepatocytes were isolated from inos /  or
wild-type C57BL/6J mice that were then pretreated for 1 h with 1 mM L-NIO to
inhibit iNOS before CO administration. Those groups exposed to CO received a
1-h pretreatment before the addition of TNF/ActD and were then returned to CO
exposure. CO did not provide protection against cell death, as evaluated via crystal
violet exclusion 12 h later in cells where iNOS expression was absent or inhibited.
Results shown are the mean   SE of triplicate wells from four independent exper-
iments. *, P   0.01 versus non-TNF/ActD and CO/TNF/ActD-treated cells.Zuckerbraun et al. 1711
luciferase reporter assay (Fig. 3 a). Again, a CM was used as
both a positive control in these low efficiency transfections
and as a standard by which to evaluate the effects of CO.
Consistent with the NF- B dependence of iNOS expres-
sion, we demonstrated decreased reporter activity in hepa-
tocytes treated with BAY 11-7082 (Fig. 3 a). Additionally,
iNOS protein was markedly increased in response to TNF- 
in the presence of CO compared with TNF-  alone (Fig. 3
b). Using hepatocytes from iNOS knockout mice (inos / )
as well as wild-type hepatocytes treated with 1 mM of the
selective iNOS inhibitor L-NIO (Calbiochem), we tested
whether CO could protect against TNF- –induced death
in the absence of iNOS activity. Hepatocytes lacking iNOS
activity were not protected significantly by CO from TNF-
 –induced cell death whereas wild-type hepatocytes were
(Fig. 3 c). The slight protection observed, which did not
reach statistical significance, in those groups treated with
CO where iNOS/NO was inhibited suggests the potential
existence of an additional protective mechanism by which
CO exerts its effects. One possibility is that other protective
genes that are activated by NF- B exert protection. Taken
together, these data show that CO requires NF- B activa-
tion and iNOS expression to provide strong protection for
hepatocytes from cell death in vitro, although we do not
rule out an apparently weaker protective mechanism that
does not require iNOS expression.
Inhaled CO Prevents Liver Failure. The above data
guided the hypothesis that inhaled CO would prevent liver
Figure 4. CO prevents TNF- /D-gal–induced liver damage. (a) Male C57BL/6 mice were pretreated for 1 h with 250 ppm CO and then administered
TNF- /D-gal. Serum was analyzed for ALT levels 6–8 h later. Those mice exposed to CO had a  74% lower serum ALT level than mice receiving air
instead of CO. Results presented as mean   SD of 18–20 mice. *, P   0.001 versus air treated. (b) Liver samples from mice treated with TNF- /D-gal
in the presence and absence of 250 ppm CO for 8 h were sectioned and stained for H&E, activated caspase 3 (as indicated by an increase in red intensity),
and TUNEL  cells (as demarcated by the increased green cellular staining). Nuclei are stained blue. Exposure to CO markedly reduced TNF- /D-gal–
induced liver damage as assessed by H&E staining. Both the increase in activated caspase 3 and TUNEL  cells were significantly less in both staining
intensity and the percentage of positively stained cells in mice treated with TNF- /D-gal in the presence of CO. Images are representative sections from
15–20 sections/liver from three to four individual mice/group. Bar, 20  m.Carbon Monoxide Prevents Liver Failure 1712
injury in the TNF- /D-gal model of fulminant hepatic fail-
ure. To test this, mice were pretreated with 250 ppm CO
for 1 h before administering 0.3  g TNF- /8 mg D-gal/
mouse i.p. and then returned to the CO exposure chamber.
Liver failure without CO occurred in 6–8 h, driven primar-
ily by apoptosis of hepatocytes, as in the in vitro model de-
scribed above (1, 13, 30). Serum ALT in mice treated with
CO was 74% lower than in those that breathed air (Fig. 4 a;
*, P   0.001). CO treatment also decreased TUNEL  cells
(a marker of cell death) and staining of activated caspase 3,
while preserving normal architecture by histological assess-
ment (Fig. 4 b). Control mice kept in air that received
TNF- /D-gal showed marked hepatic inflammation, edema,
hemorrhage, and loss of architecture (Fig. 4 b).
CO-mediated Protection against Liver Damage Requires
iNOS. Hepatic iNOS protein levels, determined by im-
munoblotting and immunohistochemistry, were increased
in livers of mice 6 h after treatment with TNF- /D-gal as
compared with air-treated controls (Fig. 5, a and b). To as-
certain whether the expression of iNOS had a functional
role, we tested whether CO would protect inos /  mice or
wild-type mice treated i.p. with 10 mg/kg of the selective
iNOS inhibitor L-NIL (dosed every 2 h). CO failed to
protect these animals as determined by serum ALT (Fig. 5
c) and histopathology (not depicted). Thus, we concluded
that the protective effect of inhaled CO in TNF- –
induced liver failure is dependent on iNOS activity.
CO-induced Protection Is Ultimately Dependent on HO-1
Activity. Based on our findings that CO-induced hepato-
protection is dependent on iNOS, plus the known hepato-
protective effects of NO and data showing that NO in-
creases the expression of HO-1 (10), we hypothesized that
CO and NO may protect through an HO-1–dependent
mechanism. Immunoblotting of liver extracts from mice
treated with CO in the presence or absence of TNF- /D-
gal showed up-regulation of HO-1 (Fig. 6 a). The addition
Figure 5. Role of iNOS in CO-induced cytoprotection
in vivo. (a) Male C57BL/6J mice were treated with air or
250 ppm CO 1 h before 0.3  g TNF- /8 mg D-gal/
mouse i.p. administration. 6 h later, livers were harvested
to evaluate iNOS expression by immunoblotting. Results
show that iNOS expression was increased modestly in air/
TNF- /D-gal–treated mice, but was markedly increased
in mice treated with TNF- /D-gal and CO. As expected,
inos /  mice showed no expression of iNOS protein. (b)
Immunostaining of iNOS expression in liver sections from
mice treated with TNF- /D-gal in the presence or absence
of CO as well as from air and CO controls that received no
TNF- /D-gal. Results show a modest increase in iNOS
expression in CO-treated mouse livers in the absence of
TNF/D-gal, however a significantly greater increase in
expression (indicated by the increase in green-stained cells)
was observed in the liver of animals treated with TNF- /
D-gal in the presence of CO, which appeared to be localized
around blood vessels. Images are representative of six separate
animals and 6–10 different sections/liver sample. Bar, 20
 m. (c) The efficacy of CO-induced protection was tested
in the absence of iNOS activity using inos /  and wild-
type mice that were treated i.p. with 5 mg/kg L-NIL, the
selective inhibitor of iNOS, dosed every 2 h. L-NIL was
administered 2 h before CO. CO-treated animals were
then pretreated (250 ppm) for 1 h before TNF- /D-gal.
In the absence of iNOS function/expression, CO is unable
to protect against liver damage as assessed by serum ALT
levels. Results are mean   SD of six to eight animals/
group. *, P   0.01 versus CO/TNF- /D-gal and air and
CO controls.Zuckerbraun et al. 1713
of the iNOS inhibitor L-NIL to these above groups, which
abrogated the protection (Fig. 5 c), also prevented the up-
regulation of HO-1 (Fig. 6 b). To test the hypothesis that
HO-1 was central to CO-elicited hepatoprotection, we
used 50  mol/kg SnPP (Frontier Scientific) s.c. as a selec-
tive inhibitor of HO-1 activity (31). SnPP very signifi-
cantly diminished the protective effects of CO in this
model (Fig. 6 c). SnPP administration in the absence of
TNF- /D-gal had no deleterious or protective effects (un-
published data). These results suggested that up-regulation
of HO-1 was important for the protective effects of CO.
To determine if up-regulation of HO-1 would also be
needed if protection was initiated by NO, mice were
treated with the pharmacological NO donor V-PYRRO/
NO. This agent is metabolized by the liver resulting in
release of NO by hepatocytes (1). V-PYRRO/NO also
provides protection after LPS/D-gal or TNF- /D-gal ad-
ministration (1). Mice were randomized and treated with
TNF- /D-gal with or without SnPP to evaluate the role of
HO-1. As previously demonstrated, V-PYYRO/NO was
protective as assayed by serum ALT. However, SnPP abrogated
the ability of this NO donor to protect against liver damage
(Fig. 6 c). Thus, we conclude that CO- or NO-initiated
hepatoprotection are at least partially dependent on HO-1.
Because these data suggest that CO and NO require HO-1
activity to protect against TNF- –induced hepatocyte
death, we tested whether protection mediated by HO-1 re-
quired iNOS activity. Using inos /  mice, we induced HO-1
via administration of CoPP. TNF- /D-gal was injected
24 h thereafter, at the peak of HO-1 expression, and liver
damage was assessed 6–8 h later. Results show that induc-
tion of HO-1 was able to significantly prevent liver injury
independently of iNOS activity with a  50% reduction in
serum ALT (Fig. 6 d). These results were confirmed using
L-NIL. Mice were pretreated with drinking water contain-
ing 4.5 mM L-NIL for 24 h. This method effectively inhib-
its NO synthase activity (32). Control mice received normal
water. Subsequently, CoPP was administered to induce
HO-1 expression and 24 h thereafter mice were challenged
with TNF- /D-gal. L-NIL treatment alone did not change
the severity of injury induced in this model. All animals re-
ceiving CoPP (with and without L-NIL) were protected
from liver injury (Fig. 6 d).
To confirm the requirement for HO-1 expression in the
observed protection by CO or NO, we isolated hepatocytes
from HO-1–null mice (hmox-1 / ) and wild-type (C57BL/
6J) littermates and treated them with TNF- /ActD in the
presence and absence of 250 ppm CO or 500  M of the
NO donor SNAP. SNAP has previously been demonstrated
to protect hepatocytes in this model (13). Air-treated wild-
type and hmox-1 /  cells exposed to TNF- /ActD under-
went cell death as expected whereas CO- or NO-treated
wild-type cells were protected in the presence of TNF- /
ActD (Fig. 7, a and b). The protection conferred by CO
and NO was however lost in cells lacking functional HO-1
(Fig. 7, a and b). We conclude that HO-1 can provide pro-
tection in this model without the involvement of iNOS,
suggesting that HO-1 or one or more of its catalytic prod-
ucts can in part exert cytoprotective effects in this model.
Inhaled CO Therapeutically Protects against APAP-induced
Hepatitis. The data above do not lend support to the use
of either of these gases for potential treatment of hepatitis
Figure 6. Interrelationship be-
tween CO/HO-1 and NO/
iNOS in providing protection
against acute liver failure. (a) Im-
munoblot of HO-1 expression in
the livers from mice administered
TNF- /D-gal in the presence
and absence of 250 ppm CO.
CO-treated mice showed a signifi-
cant increase in HO-1 expression
in both the presence and absence
of TNF- /D-gal. Blot is repre-
sentative of two independent
experiments. (b) To assess the
role of iNOS on TNF/D-gal-
induced HO-1 expression in the
liver, mice were administered 5
mg/kg L-NIL i.p. 2 h before
pretreatment with 250 ppm CO,
and then every 2 h thereafter. Control mice received L-NIL and remained in room air. Note that CO increased HO-1 expression in vehicle-treated
mice, but was unable to induce expression when iNOS was inhibited. L-NIL treatment alone had a minimal effect on HO-1 expression. Blot is repre-
sentative of two independent experiments. (c) To test the protective role of CO-induced HO-1, mice were given 50  mol/kg SnPP s.c., the selective
inhibitor of HO-1, 5 h before CO. Alternatively, the mice were given 10 mg/kg V-PYRRO (VP) s.c., an NO donor. V-PYRRO was selectively
designed to deliver NO directly to the liver. 1 h after the initial V-PYRRO dose the animals were exposed to CO for 1 h before the administration of
TNF- /D-Gal (see above). Serum ALT levels were determined 6–8 h later. Note that CO was not able to provide protection in animals where HO-1
activity was blocked. V-PYRRO, when administered 2 h before and then every 2 h thereafter, provided protection against injury as determined 8 h later
by serum ALT measurements (reference 1). Results are expressed as mean   SD of 8–10 mice/group. *, P   0.05 versus CO/TNF/D-gal–treated mice.
(d) Wild-type C57BL/6J mice were pretreated for 24 h with 4.5 mM L-NIL in the drinking water as previously described (reference 32). These mice
and inos /  mice were then administered CoPP. L-NIL was maintained in the water throughout the experiment. Control and inos /  mice received normal
drinking water. 24 h after CoPP, TNF- /D-gal was administered and serum ALT was determined 6–8 h later. Note that induction of HO-1 provides
protection regardless of the presence of iNOS. Results are mean   SD of six to eight mice/group. *, P   0.001 versus Air/TNF and L-NIL/TNF.Carbon Monoxide Prevents Liver Failure 1714
clinically. In fact, the TNF /D-gal model does not lend it-
self to such an analysis given the rapidly fatal course of the
disease. Therefore, we tested CO administration in another
model of hepatitis in which the disease course is less vio-
lent: APAP-induced hepatitis. In Fig. 8, the results of ad-
ministering CO before and 4 h after administration of
APAP to mice and the assessment of the results 16 h later
(20 h after APAP) are shown. This protocol was designed
to allow the hepatitis to begin to develop for 4 h before
giving CO. CO administration still very significantly re-
duced damage to the liver as assessed by serum ALT (622  
44 vs. 175   137, P   0.01, as compared with controls;
Fig 8). This protection was similar to that observed in a
separate group of animals that had been pretreated with
CO before APAP. These data support the potential thera-
peutic use of CO in a clinically relevant situation where
treatment would begin after the initiation of the insult.
Discussion
These results demonstrate that a low concentration of
CO can protect against TNF- /D-gal–induced fulminant
hepatitis and illustrate a unique and previously unrecog-
nized dependence on both HO-1 and iNOS in the CO-
induced protection of livers from damage by TNF- /D-gal.
The model (Fig. 9) we propose is that CO-mediated pro-
tection operates by activating NF- B, which in the pres-
ence of an inflammatory stimulus leads to the up-regulation
of iNOS with the consequent production of NO. In addi-
tion to the induction of iNOS, other NF- B–dependent
antiapoptotic/protective genes might be induced (21, 26,
27). These protective genes may account for the relatively
Figure 8. Therapeutic effects of CO against APAP-induced hepato-
toxicity. Male C57BL/6J mice were exposed to 250 ppm CO either 1 h
before or 4 h after the i.p. administration of 500 mg/kg APAP. The mice
were then maintained in CO for the duration of the experiment. Serum
ALT levels were determined 20 h after APAP administration. Control mice
received APAP and were maintained in air. *, P   0.01 versus APAP-
treated mice in air. Results are mean   SD of four to eight mice/group.
Figure 7. HO-1 is required for CO- or NO-induced cytoprotection
from TNF- /ActD-induced hepatocyte cell death. (a) Mouse hepatocytes
isolated from hmox-1 /  or wild-type C57BL/6J mice were pretreated for
1 h with 250 ppm CO followed by treatment with TNF- /ActD. Viability
was assayed as described in Materials and Methods. CO significantly protected
wild-type hepatocytes, but was unable to protect hepatocytes isolated
from hmox-1 /  mice. (b) 500  M of the NO donor, SNAP, significantly
protected against cell death in wild-type hepatocytes, but did not provide sig-
nificant protection against cell death in hepatocytes isolated from hmox-1 / 
mice.  *, P    0.01 versus non–TNF- /ActD-treated cells and versus
TNF- /ActD-treated cells that were also treated with SNAP or CO.
Figure 9. CO signaling in the liver. The figure depicts the concept of a
cycle where exogenous CO mediates its therapeutic effects through a series of
steps, each of which is essential for hepatoprotection. We speculate in the
text about the potential explanations for the need for HO-1 expression to
mediate the protection provided by exogenous CO.Zuckerbraun et al. 1715
weak (and not significant) protection seen with exogenous
CO even when iNOS was inhibited. During the 1-h pre-
treatment with CO and before the cells were treated with
TNF- , significant activation of NF- B was present,
which could be part of the priming of the cellular apparatus
discussed above. The activation of NF- B by CO may in
part result from a mild increase in reactive oxygen species
generation originating from the mitochondria (preliminary
observations). 1 h might also permit time for expression of
NF- B–dependent antiapoptotic genes. The next step in
our model would lead to NO production after the up-reg-
ulation of iNOS. NO leads to up-regulation of HO-1, the
activity of which confers protective effects. The protective
effect of HO-1 could be due to removal of heme or to any
one or more of its three products: CO, biliverdin/biliru-
bin, or iron/ferritin (31). Given that we administer exoge-
nous CO throughout the duration of these experiments, it
seems unlikely that endogenously produced CO alone me-
diates HO-1 protection. However, the combination of CO
with other products of HO-1 or these other products act-
ing individually might be involved.
The primary goal of these studies was to examine the
potential interdependence of CO and NO in the therapeu-
tic effects these two gases have on hepatitis induced by
TNF- /D-gal, and the potential role of iNOS and HO-1
in the process. In these experiments CO or NO (or in the
case of HO-1 induction, CoPP) was given as a pretreat-
ment and thus these experiments do not address the hy-
pothesis that CO may have therapeutic benefit even after
the hepatitis process has started. How much CO is deliv-
ered to the liver by inhalation is unknown and well near
impossible to measure with present technology. CO bound
to hemoglobin has an off rate that presumably helps to de-
termine the amount of CO that would reach the liver in
addition to the high diffusion and nonreactivity of CO.
The TNF- /D-gal model is not a good one for testing
such a hypothesis given the rapidity with which hepatic ne-
crosis, circulatory collapse, and death occurs after TNF- /
D-gal administration. Therefore, we administered CO in a
clinically relevant model of APAP-induced hepatitis that
has a time course similar to the development of acute hepa-
titis in humans (33). Our data demonstrate that exposure to
CO 4 h after i.p. administration of 500 mg/kg APAP re-
sulted in a 62% reduction in liver injury (Fig. 8). In this
model of APAP-induced liver injury, mice show signs of
hepatitis as early as 2–4 h after APAP administration (34,
35) with hepatocyte cell death and lethality occurring by
24–48 h. Thus, CO was administered after the initiation of
liver injury. Preliminary analyses of reduced glutathione
levels in liver homogenates from these animals showed that
CO prevented the APAP-induced decrease in glutathione
levels, which points to CO maintaining the antioxidant po-
tential of the tissue (not depicted). Consistent with the data
in the APAP model are our results in a murine model of
hemorrhagic shock where the therapeutic initiation of in-
haled CO during resuscitation after a 2.5-h shock phase re-
sulted in protection against liver injury ( 65% reduction in
serum ALT at 24 h, P   0.01; n   6–10/group). Further
investigations into the potential therapeutic benefit of in-
haled CO delivery as a therapeutic adjunct after an insult
that leads to hepatitis are clearly needed.
In summary, using a model of liver injury driven princi-
pally by TNF- –induced apoptosis, we show the follow-
ing. First, inhaled CO can prevent hepatitis in this model.
Second, protection by CO requires generation of a second
gaseous molecule, NO. Third, NO exerts its beneficial ef-
fects, at least in part, via up-regulation of HO-1. Lastly,
up-regulation of HO-1 is protective without a need for
iNOS/NO activity, i.e., without an obligate continuation
of the cycle. Taken together, these data demonstrate for the
first time a functional relationship between HO-1/CO and
iNOS/NO. We propose a novel protective cycle that relies
on two gas molecules and their respective enzymes. To-
gether, CO, NO, and HO-1 beneficially modulate the ap-
optotic/inflammatory state. Whether CO treatment can be
used clinically was not the main question we probed in this
paper. However, our limited but significant data in the
APAP model suggests that CO exposure might prove ben-
eficial as a therapy to ameliorate hepatic injury even if
given shortly after the hepatic injury starts.
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